- Home»
- The Billing Beat Newsletter»
- BCBS – Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies
BCBS – Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies
June 3, 2021This review focuses on “expanded” panels, which are defined as molecular panels that test a wide variety of genetic markers in cancers without regard for whether a specific targeted treatment has demonstrated benefit. This approach may result in treatment different from that usually selected for a patient based on the type and stage of cancer. Effective 05-11-2021 In Coding section: Added code: 0224U.
The source page for this article has moved or has expired.
Please visit the Billing Beat News or Beyond Billing Blog for relevant information or search our site for specific information related to this article.
Original source URL:
https://www.bcbsks.com/CustomerService/Providers/MedicalPolicies/policies/policies/ComprehensiveGenomicProfiling_SelectingTargetedCancerTherapies_2021-05-11.pdf